30 / 38
ICI in patients with baseline autoimmune diseases
Abdel-Wahab – Ann Intern Med 2018 * Johanson – JAMA Oncol 2016 * Shadendorf – JCO 2015 * Danlos – Eur J Cancer 2018
41% had disease exacerbation during ICIs therapy,
No difference in onset of AE’s in patients with active
vs
. inactive baseline AD.
• In phase II&III, mOS: 11.4 mo
• 30 melanoma with baseline AD:
• 43% receiving IS therapy
• 27% had exacerbations
• 33% of grade 3-5 ir-AE’s
• Response Rate 20%
Median OS: 12.5 mo.
Melanoma and Ipilimumab